{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:21:18Z","timestamp":1783030878389,"version":"3.54.6"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.semradonc.2026.151031","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:26:50Z","timestamp":1781350010000},"page":"151031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Integrative Oncology for Prostate Cancer: A Narrative Review"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-9749","authenticated-orcid":false,"given":"Kevin T.","family":"Liou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Metri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert U.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Ajay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2026.151031_bib0001","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Updated 2025. Accessed December 12, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0002","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1093\/jnci\/djaf179","article-title":"Stat bite: Prevalence of cancer in the United States in 2022","volume":"117","author":"Noone","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2026.151031_bib0003","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.5888\/pcd18.210006","article-title":"Cancer incidence projections in the United States between 2015 and 2050","volume":"18","author":"Weir","year":"2021","journal-title":"Prev Chronic Dis"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0004","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.semradonc.2026.151031_bib0005","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/jamaoncol.2024.4397","article-title":"Long-term adverse effects and complications after prostate cancer treatment","volume":"10","author":"Unger","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0006","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7047","article-title":"Symptom burden and survivorship care for patients with prostate cancer on androgen deprivation therapy","volume":"23","author":"Sentana-Lledo","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejon.2014.12.007","article-title":"Identifying the unmet supportive care needs of men living with and beyond prostate cancer: A systematic review","volume":"19","author":"Paterson","year":"2015","journal-title":"Eur J Oncol Nurs"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0008","first-page":"5511","article-title":"Long-term unmet supportive care needs of prostate cancer survivors: 15-year follow-up from the NSW Prostate Cancer Care and Outcomes Study","volume":"28","author":"Mazariego","year":"2020","journal-title":"Support Care Cancer"},{"issue":"52","key":"10.1016\/j.semradonc.2026.151031_bib0009","article-title":"A comprehensive definition for integrative oncology","volume":"2017","author":"Witt","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JOP.18.00554","article-title":"Putting integrative oncology into practice: Concepts and approaches","volume":"15","author":"Latte-Naor","year":"2019","journal-title":"J Oncol Pract"},{"issue":"52","key":"10.1016\/j.semradonc.2026.151031_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgx004","article-title":"Growth of integrative medicine at leading cancer centers between 2009 and 2016: A systematic analysis of NCI-designated Comprehensive cancer center websites","volume":"2017","author":"Yun","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0012","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1089\/acm.2021.0102","article-title":"Availability of integrative medicine therapies at National Cancer Institute-designated Comprehensive Cancer centers and Community hospitals","volume":"27","author":"Desai","year":"2021","journal-title":"J Altern Complement Med"},{"key":"10.1016\/j.semradonc.2026.151031_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/OP.2025.21.10_suppl.46","article-title":"Association of Hospitals' organizational characteristics and market factors offering integrative medicine services to adult patients with cancer","author":"Ajani","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"34","key":"10.1016\/j.semradonc.2026.151031_bib0014","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01357","article-title":"Integrative medicine for pain management in oncology: Society for integrative oncology-ASCO guideline","volume":"40","author":"Mao","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.semradonc.2026.151031_bib0015","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.24.00541","article-title":"Management of fatigue in adult survivors of cancer: A SCO-Society for Integrative Oncology Guideline update","volume":"42","author":"Bower","year":"2024","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.semradonc.2026.151031_bib0016","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.23.00857","article-title":"Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO Guideline","volume":"41","author":"Carlson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"71","key":"10.1016\/j.semradonc.2026.151031_bib0017","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jncimonographs\/lgaf025","article-title":"History informing the future of exercise oncology","volume":"2025","author":"Galvao","year":"2025","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0018","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41585-021-00476-y","article-title":"Exercise-induced myokines and their effect on prostate cancer","volume":"18","author":"Kim","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0019","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.jsams.2019.05.003","article-title":"The exercise and sports science Australia position statement: Exercise medicine in cancer management","volume":"22","author":"Hayes","year":"2019","journal-title":"J Sci Med Sport"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-084412","article-title":"Prostate cancer survivorship essentials for men with prostate cancer on androgen deprivation therapy: Protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study)","volume":"14","author":"Green","year":"2024","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.semradonc.2026.151031_bib0021","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1007\/s40279-025-02311-5","article-title":"Periodizing exercise medicine prescription for patients with cancer: A narrative opinion","volume":"55","author":"Bettariga","year":"2025","journal-title":"Sports Med"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0022","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1249\/JES.0000000000000323","article-title":"Exercise mediates myokine release and tumor suppression in prostate cancer independent of androgen signaling","volume":"51","author":"Kim","year":"2023","journal-title":"Exerc Sport Sci Rev"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0023","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2010.31.5226","article-title":"Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study","volume":"29","author":"Kenfield","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0024","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1249\/MSS.0000000000002783","article-title":"Myokine expression and tumor-suppressive effect of serum after 12 wk of exercise in prostate cancer patients on ADT","volume":"54","author":"Kim","year":"2022","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41391-022-00504-x","article-title":"Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth","volume":"25","author":"Kim","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0026","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41391-022-00624-4","article-title":"Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer","volume":"26","author":"Kim","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0027","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1158\/0008-5472.CAN-10-3932","article-title":"Physical activity after diagnosis and risk of prostate cancer progression: Data from the cancer of the prostate strategic urologic research endeavor","volume":"71","author":"Richman","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2502760","article-title":"Structured exercise after adjuvant chemotherapy for colon cancer","volume":"393","author":"Courneya","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0029","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1186\/s12885-024-12530-0","article-title":"Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study","volume":"24","author":"Kim","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semradonc.2026.151031_bib0030","article-title":"Potential role of exercise induced extracellular vesicles in prostate cancer suppression","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0031","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jshs.2023.12.001","article-title":"Suppressive effects of exercise-conditioned serum on cancer cells: A narrative review of the influence of exercise mode, volume, and intensity","volume":"13","author":"Bettariga","year":"2024","journal-title":"J Sport Health Sci"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0032","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.prro.2021.01.005","article-title":"Effect of exercise adjunct to radiation and androgen deprivation therapy on patient-reported treatment toxicity in men with prostate cancer: a secondary analysis of 2 randomized controlled trials","volume":"11","author":"Schumacher","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0033","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12885-025-13555-9","article-title":"Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy \u2013 protocol for the ERADICATE study: a phase II randomised controlled trial","volume":"25","author":"Schumacher","year":"2025","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0034","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ijrobp.2021.06.034","article-title":"Effects of exercise during radiation therapy on physical function and treatment-related side Effects in men with prostate cancer: a systematic review and meta-analysis","volume":"111","author":"Schumacher","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2026.151031_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103995","article-title":"Effects and moderators of exercise medicine on cardiometabolic outcomes in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis","volume":"186","author":"Lopez","year":"2023","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0036","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1249\/MSS.0000000000002843","article-title":"Interventions for improving body composition in men with prostate cancer: A systematic review and network meta-analysis","volume":"54","author":"Lopez","year":"2022","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0037","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41391-021-00363-y","article-title":"Body weight, fat mass and metabolic complications during androgen deprivation therapy: Should urologists recommend exercise and diet to help patients overcome toxicities?","volume":"24","author":"Galv\u00e3o","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0038","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41391-021-00327-2","article-title":"Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: Modifying effects of exercise from a year-long randomized controlled trial","volume":"24","author":"Galv\u00e3o","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0039","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bju.14505","article-title":"Immediate versus delayed exercise in men initiating androgen deprivation: Effects on bone density and soft tissue composition","volume":"123","author":"Taaffe","year":"2019","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.euo.2024.09.012","article-title":"Immediate versus delayed exercise on health-related quality of life in patients initiating androgen deprivation therapy: Results from a year-long randomised trial","volume":"8","author":"Taaffe","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0041","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1249\/MSS.0000000000001831","article-title":"Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients","volume":"51","author":"Newton","year":"2019","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0042","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.eururo.2017.02.019","article-title":"Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: A year-long randomised controlled trial","volume":"72","author":"Taaffe","year":"2017","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.semradonc.2026.151031_bib0043","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1249\/MSS.0000000000001277","article-title":"Exercise improves VO2max and body composition in androgen deprivation therapy-treated prostate cancer patients","volume":"49","author":"Wall","year":"2017","journal-title":"Med Sci Sports Exerc"},{"issue":"18","key":"10.1016\/j.semradonc.2026.151031_bib0044","doi-asserted-by":"crossref","first-page":"16563","DOI":"10.1007\/s00432-023-05409-3","article-title":"Prehabilitative versus rehabilitative exercise in prostate cancer patients undergoing prostatectomy","volume":"149","author":"Singh","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.semradonc.2026.151031_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euros.2022.07.008","article-title":"Which type of exercise during radiation therapy is optimal to improve fatigue and quality of life in men with prostate cancer? A Bayesian network analysis","volume":"43","author":"Xiong","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.semradonc.2026.151031_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111427","article-title":"Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer patients: A secondary analysis of two randomized controlled trials","volume":"151","author":"Newton","year":"2021","journal-title":"Exp Gerontol"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0047","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urolonc.2022.11.016","article-title":"Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention","volume":"41","author":"Langlais","year":"2023","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0048","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0413","article-title":"Exercise and psychosexual education to improve sexual function in men with prostate cancer: A randomized clinical trial","volume":"8","author":"Galv\u00e3o","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0049","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bmjspcare-2020-002706","article-title":"Exercise intervention and sexual function in advanced prostate cancer: A randomised controlled trial","volume":"12","author":"Galv\u00e3o","year":"2022","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.semradonc.2026.151031_bib0050","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-025-01882-6","article-title":"Structured and supervised pelvic floor muscle training following confirmed contraction in post-prostatectomy urinary incontinence: A systematic review of randomized controlled trials","author":"Gerlegiz","year":"2025","journal-title":"J Cancer Surviv"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0051","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41391-021-00442-0","article-title":"Associations of fat and muscle mass with overall survival in men with prostate cancer: A systematic review with meta-analysis","volume":"25","author":"Lopez","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0052","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17041441","article-title":"Does physical activity regulate prostate carcinogenesis and prostate cancer outcomes? A narrative review","volume":"17","author":"Capece","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1249\/MSS.0000000000003848","article-title":"Effects of resistance versus high-intensity interval training on myokines and cancer cell suppression in breast cancer survivors: A randomized trial","volume":"58","author":"Bettariga","year":"2026","journal-title":"Med Sci Sports Exerc"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0054","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/jgs.19312","article-title":"Characteristics of prostate cancer patients seeking integrative medicine","volume":"73","author":"Silberlust","year":"2025","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1940-6207.CAPR-14-0442","article-title":"Dietary patterns after prostate cancer diagnosis in relation to disease-specific and total mortality","volume":"8","author":"Yang","year":"2015","journal-title":"Cancer Prev Res (Phila)"},{"issue":"17","key":"10.1016\/j.semradonc.2026.151031_bib0056","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/healthcare13172201","article-title":"The impact of different dietary patterns on mortality and prognosis after non-metastatic prostate cancer diagnosis: A systematic review","volume":"13","author":"Htet","year":"2025","journal-title":"Healthcare (Basel)"},{"issue":"10","key":"10.1016\/j.semradonc.2026.151031_bib0057","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/nu8100626","article-title":"A Western dietary pattern increases prostate cancer risk: A systematic review and meta-analysis","volume":"8","author":"Fabiani","year":"2016","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0058","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/nu13020496","article-title":"Dietary factors and prostate cancer development, progression, and reduction","volume":"13","author":"Oczkowski","year":"2021","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0059","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.eururo.2025.07.017","article-title":"Dietary patterns in prostate cancer prevention and management: A systematic review of prospective cohort studies and randomized clinical trials","volume":"88","author":"Lin","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2026.151031_bib0060","article-title":"Effect of postdiagnosis diet and lifestyle on clinical outcomes in prostate cancer survivors: A systematic review","author":"Allen","year":"2025","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0061","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9053","article-title":"Plant-based diets and disease progression in men with prostate cancer","volume":"7","author":"Liu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0062","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ajcn\/nqab365","article-title":"Association of plant-based diet index with prostate cancer risk","volume":"115","author":"Loeb","year":"2022","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0063","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/cncr.35172","article-title":"Plant-based diet associated with better quality of life in prostate cancer survivors","volume":"130","author":"Loeb","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0064","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/pros.23457","article-title":"Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study","volume":"78","author":"Bauer","year":"2018","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.2019.20207","article-title":"Effect of a behavioral intervention to increase vegetable consumption on cancer progression among men with early-stage prostate cancer: The MEAL randomized clinical trial","volume":"323","author":"Parsons","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.semradonc.2026.151031_bib0066","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-19-3873","article-title":"A randomized controlled trial of a 6-month low-carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and prostate study 2 (CAPS2)","volume":"26","author":"Freedland","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0067","first-page":"874","article-title":"Behavioral stress accelerates prostate cancer development in mice","volume":"123","author":"Hassan","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0068","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21903","article-title":"Neighborhood disadvantage and prostate tumor RNA expression of stress-related genes","volume":"7","author":"Boyle","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"15","key":"10.1016\/j.semradonc.2026.151031_bib0069","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/pros.24052","article-title":"Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial","volume":"80","author":"Wiggins","year":"2020","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0070","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.2007.13.5905","article-title":"Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review","volume":"26","author":"Velicer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0071","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.urology.2005.01.035","article-title":"Supplement use among men with prostate cancer","volume":"66","author":"Wiygul","year":"2005","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0072","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0090-4295(03)00668-X","article-title":"Use of complementary\/alternative medicine by men diagnosed with prostate cancer: Prevalence and characteristics","volume":"62","author":"Boon","year":"2003","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0073","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.urology.2005.06.003","article-title":"Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer","volume":"66","author":"Chan","year":"2005","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0074","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0090-4295(01)01491-1","article-title":"Rates of unconventional medical therapy use in patients with prostate cancer: Standard history versus directed questions","volume":"59","author":"Jones","year":"2002","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1534735403256207","article-title":"A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer","volume":"2","author":"Eng","year":"2003","journal-title":"Integr Cancer Ther"},{"key":"10.1016\/j.semradonc.2026.151031_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9276380","article-title":"The biological activities of vitamin D and its receptor in relation to calcium and bone homeostasis, cancer, immune and cardiovascular systems, skin biology, and oral health","volume":"2018","author":"Khammissa","year":"2018","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0077","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/metabo11040255","article-title":"Vitamin D sources, metabolism, and deficiency: Available compounds and guidelines for its treatment","volume":"11","author":"Dominguez","year":"2021","journal-title":"Metabolites"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0078","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0079","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i6.108113","article-title":"Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy","volume":"16","author":"Hasan","year":"2025","journal-title":"World J Clin Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0080","first-page":"847","article-title":"Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)","volume":"11","author":"Ahonen","year":"2000","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.semradonc.2026.151031_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2025.106675","article-title":"The double disparity: vitamin D deficiency and lethal prostate cancer in black men","volume":"247","author":"Duraki","year":"2025","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0082","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ijc.27327","article-title":"Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade","volume":"131","author":"Gilbert","year":"2012","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0083","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1371\/journal.pmed.0040103","article-title":"A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer","volume":"4","author":"Li","year":"2007","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0084","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.urolonc.2024.12.260","article-title":"Harnessing nature's therapeutic potential: A review of natural products in prostate cancer management","volume":"43","author":"Metri","year":"2025","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(01)63236-1","article-title":"Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)","volume":"159","author":"Gross","year":"1998","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0086","first-page":"3605","article-title":"A phase II trial of calcitriol and naproxen in recurrent prostate cancer","volume":"29","author":"Srinivas","year":"2009","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0087","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1210\/jc.2012-1451","article-title":"Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance","volume":"97","author":"Marshall","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0088","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1210\/jc.2012-4019","article-title":"Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients","volume":"98","author":"Wagner","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0089","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/1078-1439(95)00061-5","article-title":"Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer","volume":"1","author":"Osborn","year":"1995","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0090","first-page":"4077","article-title":"Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer","volume":"9","author":"Liu","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0091","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.coc.0000136020.27904.9c","article-title":"High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer","volume":"27","author":"Beer","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0092","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000169261.42298.e6","article-title":"High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: A phase i\/ii study","volume":"174","author":"Tiffany","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2026.151031_bib0093","doi-asserted-by":"crossref","first-page":"8680","DOI":"10.1158\/1078-0432.CCR-05-1237","article-title":"Phase I\/II study of 19-nor-1a-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer","volume":"11","author":"Schwartz","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.semradonc.2026.151031_bib0094","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.21890","article-title":"Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer","volume":"106","author":"Trump","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.semradonc.2026.151031_bib0095","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1158\/1078-0432.CCR-07-4274","article-title":"Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer","volume":"14","author":"Attia","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0096","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/cncr.24973","article-title":"Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration-resistant prostate cancer","volume":"16","author":"Chadha","year":"2010","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.semradonc.2026.151031_bib0097","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.semradonc.2026.151031_bib0098","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.14694\/EdBook_AM.2015.35.e567","article-title":"Bone health in adults treated with endocrine therapy for early breast or prostate cancer","author":"Van Poznak","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.semradonc.2026.151031_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.semradonc.2026.151031_bib0100","unstructured":"NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines\u00ae) prostate Cancer (Version 4.2026): National Comprehensive Cancer Network; [December 2025]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"issue":"10","key":"10.1016\/j.semradonc.2026.151031_bib0101","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/nu13103328","article-title":"Relative efficacy of vitamin D2 and vitamin D3 in improving vitamin D status: systematic review and meta-analysis","volume":"13","author":"Balachandar","year":"2021","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0102","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/jc.2012-4287","article-title":"Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial","volume":"98","author":"Lehmann","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2026.151031_bib0103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.freeradbiomed.2014.03.035","article-title":"Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy","volume":"72","author":"Jiang","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0104","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/antiox10050634","article-title":"Vitamin E beyond its antioxidant label","volume":"10","author":"Ungurianu","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0105","first-page":"1047-1048","volume":"12","author":"Traber","year":"2021","journal-title":"Vitamin E. Adv Nutr"},{"key":"10.1016\/j.semradonc.2026.151031_bib0106","series-title":"Present Knowledge in Nutrition.","first-page":"115","article-title":"Vitamin E","author":"Traber","year":"2020"},{"key":"10.1016\/j.semradonc.2026.151031_bib0107","first-page":"855","article-title":"Alpha-tocopherol: looking beyond an antioxidant","volume":"15","author":"Engin","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.semradonc.2026.151031_bib0108","series-title":"StatPearls","article-title":"Vitamin E","author":"Medina","year":"2025"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2008.862","article-title":"Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial","volume":"301","author":"Gaziano","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2188\/jea.JE20220235","article-title":"Dietary consumption of antioxidant vitamins in relation to prostate cancer risk in Japanese men: The japan public health center-based prospective study","volume":"34","author":"Ge","year":"2024","journal-title":"J Epidemiol"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0111","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/nu15010014","article-title":"Vitamin E intake and risk of prostate cancer: A meta-analysis","volume":"15","author":"Loh","year":"2022","journal-title":"Nutrients"},{"issue":"14","key":"10.1016\/j.semradonc.2026.151031_bib0112","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the selenium and Vitamin E cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.semradonc.2026.151031_bib0113","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3390\/nu15122677","article-title":"Association between vitamin A and E forms and prostate cancer risk in the Singapore Prostate Cancer Study","volume":"15","author":"Loh","year":"2023","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10637-016-0334-y","article-title":"A multicenter phase 1\/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer","volume":"34","author":"Kyriakopoulos","year":"2016","journal-title":"Invest New Drugs"},{"issue":"11\u201312","key":"10.1016\/j.semradonc.2026.151031_bib0115","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1080\/01635581.2020.1857412","article-title":"Plasma, prostate and urine levels of tocopherols and metabolites in men after supplementation with a \u03b3-tocopherol-rich vitamin E mixture","volume":"73","author":"Goodin","year":"2021","journal-title":"Nutr Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and Vitamin E cancer prevention trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0117","doi-asserted-by":"crossref","first-page":"djt456","DOI":"10.1093\/jnci\/djt456","article-title":"Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk","volume":"106","author":"Kristal","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.semradonc.2026.151031_bib0118","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1001\/jama.2022.8970","article-title":"Vitamin, mineral, and multivitamin supplementation to prevent cardiovascular disease and cancer: US Preventive Services Task Force Recommendation Statement","volume":"327","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0119","doi-asserted-by":"crossref","DOI":"10.3390\/ph16091250","article-title":"Selenium in prostate cancer: Prevention, progression, and treatment","volume":"16","author":"Jiang","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/pros.22573","article-title":"Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer","volume":"73","author":"Algotar","year":"2013","journal-title":"Prostate"},{"issue":"22","key":"10.1016\/j.semradonc.2026.151031_bib0121","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2008.18.8938","article-title":"Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer","volume":"27","author":"Chan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0122","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/0008-5472.CAN-04-3535","article-title":"Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer","volume":"65","author":"Li","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0123","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00008571-200303000-00004","article-title":"The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria","volume":"13","author":"Sutton","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"8","key":"10.1016\/j.semradonc.2026.151031_bib0124","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1940-6207.CAPR-09-0143","article-title":"Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer","volume":"3","author":"Stratton","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0125","doi-asserted-by":"crossref","first-page":"dju360","DOI":"10.1093\/jnci\/dju360","article-title":"Selenium supplementation and prostate cancer mortality","volume":"107","author":"Kenfield","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0126","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10654-018-0422-8","article-title":"Selenium exposure and the risk of type 2 diabetes: A systematic review and meta-analysis","volume":"33","author":"Vinceti","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0127","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7326\/0003-4819-147-4-200708210-00175","article-title":"Effects of long-term selenium supplementation on the incidence of type 2 diabetes","volume":"147","author":"Stranges","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0128","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/10408398.2021.1963664","article-title":"Zinc nutrition and dietary zinc supplements","volume":"63","author":"Duan","year":"2023","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.semradonc.2026.151031_bib0129","unstructured":"National Institutes of Health OoDS. Zinc: Fact Sheet for Health Professionals: National Institutes of Health; 2025. Available from: https:\/\/ods.od.nih.gov\/factsheets\/zinc-healthprofessional\/."},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0130","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1093\/jn\/132.11.3422","article-title":"Mineral intakes of elderly adult supplement and non-supplement users in the third national health and nutrition examination survey","volume":"132","author":"Ervin","year":"2002","journal-title":"J Nutr"},{"key":"10.1016\/j.semradonc.2026.151031_bib0131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2025.127605","article-title":"Role of zinc homeostasis in the prevention of prostate diseases","volume":"88","author":"Chen","year":"2025","journal-title":"J Trace Elem Med Biol"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0132","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-4-32","article-title":"hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer","volume":"4","author":"Franklin","year":"2005","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0133","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF02552202","article-title":"Zinc in the human prostate gland: normal, hyperplastic and cancerous","volume":"29","author":"Zaicck","year":"1997","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0134","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1097-0045(19990801)40:3<200::AID-PROS8>3.0.CO;2-3","article-title":"Inhibitory effect of zinc on human prostatic carcinoma cell growth","volume":"40","author":"Liang","year":"1999","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299398","article-title":"The association between zinc and prostate cancer development: A systematic review and meta-analysis","volume":"19","author":"Shahrokhi Nejad","year":"2024","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.semradonc.2026.151031_bib0136","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s10654-022-00922-0","article-title":"Zinc supplement use and risk of aggressive prostate cancer: A 30-year follow-up study","volume":"37","author":"Zhang","year":"2022","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0137","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JU.0000000000003080","article-title":"Post-diagnostic zinc supplement use and prostate cancer survival among men with nonmetastatic prostate cancer","volume":"209","author":"Zhang","year":"2023","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0138","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3945\/ajcn.110.004804","article-title":"Dietary zinc and prostate cancer survival in a Swedish cohort","volume":"93","author":"Epstein","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0139","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02134-y","article-title":"High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer","volume":"40","author":"B\u00f6ttger","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.semradonc.2026.151031_bib0140","doi-asserted-by":"crossref","first-page":"11105","DOI":"10.1073\/pnas.0804226105","article-title":"Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice","volume":"105","author":"Chen","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semradonc.2026.151031_bib0141","unstructured":"Abdullah M, Jamil RT, Attia FN: Vitamin C (Ascorbic Acid). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499877\/"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0142","first-page":"1129","article-title":"Micronutrient intake and risk of prostate cancer in a cohort of middle-aged, Danish men","volume":"24","author":"Roswall","year":"2013","journal-title":"Cancer Causes Control"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0143","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7150\/jca.12162","article-title":"Association between dietary vitamin C intake and risk of prostate cancer: A meta-analysis involving 103,658 subjects","volume":"6","author":"Bai","year":"2015","journal-title":"J Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0144","doi-asserted-by":"crossref","first-page":"517","DOI":"10.21037\/tau.2017.04.42","article-title":"Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: A single-arm phase II trial","volume":"6","author":"Nielsen","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"8","key":"10.1016\/j.semradonc.2026.151031_bib0145","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/2767-9764.CRC-24-0225","article-title":"High-dose intravenous vitamin C combined with docetaxel in men with metastatic castration-resistant prostate cancer: A randomized placebo-controlled phase II trial","volume":"4","author":"Paller","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0146","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2713511","article-title":"Lycopene: food sources, biological activities, and human health benefits","volume":"2021","author":"Khan","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.semradonc.2026.151031_bib0147","series-title":"In: Advances in Food and Nutrition Research","first-page":"99","article-title":"Lycopene","volume":"51","author":"Rao","year":"2006"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0148","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/pcan.2017.25","article-title":"Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis","volume":"20","author":"Rowles","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0149","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annepidem.2009.03.017","article-title":"Serum lycopene and the risk of cancer: The Kuopio ischaemic heart disease risk factor (KIHD) study","volume":"19","author":"Karppi","year":"2009","journal-title":"Ann Epidemiol"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0150","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/s12916-025-04440-0","article-title":"Lycopene intake and prostate cancer risk in men at high cardiovascular risk: A prospective cohort study","volume":"23","author":"L\u00f3pez-Sol\u00eds","year":"2025","journal-title":"BMC Med"},{"issue":"14","key":"10.1016\/j.semradonc.2026.151031_bib0151","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/jnci\/djm037","article-title":"The U.S. Food and Drug Administration's evidence-based review for qualified health claims: Tomatoes, lycopene, and cancer","volume":"99","author":"Kavanaugh","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0152","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.clnu.2016.06.014","article-title":"Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA","volume":"36","author":"Paur","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1016\/j.semradonc.2026.151031_bib0153","first-page":"1","article-title":"Results of a randomized clinical trial of the action of several doses of lycopene in localized prostate cancer: Administration prior to radical prostatectomy","volume":"1","author":"Kumar","year":"2008","journal-title":"Clin Med Urol"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0154","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.urology.2005.12.035","article-title":"Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy","volume":"67","author":"Clark","year":"2006","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01635580701413934","article-title":"Lycopene and soy isoflavones in the treatment of prostate cancer","volume":"59","author":"Vaishampayan","year":"2007","journal-title":"Nutr Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0156","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1078-1439(04)00122-X","article-title":"Lycopene: A novel drug therapy in hormone refractory metastatic prostate cancer","volume":"22","author":"Ansari","year":"2004","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0157","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1464-410X.2003.04370.x","article-title":"A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer","volume":"92","author":"Ansari","year":"2003","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0158","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.juro.2008.11.012","article-title":"Lycopene for advanced hormone refractory prostate cancer: A prospective, open phase II pilot study","volume":"181","author":"Schwenke","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2026.151031_bib0159","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112226","article-title":"A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer","volume":"143","author":"Zhuang","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0160","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/antiox10030342","article-title":"Lycopene: A critical review of digestion, absorption, metabolism, and excretion","volume":"10","author":"Arballo","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0161","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0091-7435(92)90041-F","article-title":"Green tea composition, consumption, and polyphenol chemistry","volume":"21","author":"Graham","year":"1992","journal-title":"Prev Med"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0162","first-page":"372","article-title":"Green tea","volume":"5","year":"2000","journal-title":"Altern Med Rev"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0163","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/01635581.2011.570895","article-title":"Green tea and black tea consumption and prostate cancer risk: An exploratory meta-analysis of observational studies","volume":"63","author":"Zheng","year":"2011","journal-title":"Nutr Cancer"},{"issue":"13","key":"10.1016\/j.semradonc.2026.151031_bib0164","doi-asserted-by":"crossref","first-page":"e6426","DOI":"10.1097\/MD.0000000000006426","article-title":"Green tea and the risk of prostate cancer","volume":"96","author":"Guo","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.semradonc.2026.151031_bib0165","first-page":"1635","article-title":"Green and black tea intake in relation to prostate cancer risk among Singapore Chinese","volume":"23","author":"Montague","year":"2012","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0166","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.11550","article-title":"Protective effect of green tea against prostate cancer: A case-control study in southeast China","volume":"108","author":"Jian","year":"2004","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0167","article-title":"Green tea (Camellia sinensis) for the prevention of cancer","volume":"2021","author":"Filippini","year":"2020","journal-title":"Cochrane Libr"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0168","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/0008-5472.CAN-05-1145","article-title":"Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study","volume":"66","author":"Bettuzzi","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0169","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2008.03.100","article-title":"Chemoprevention of human prostate cancer by green tea catechins: Two years later. A follow-up update","volume":"54","author":"Brausi","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4081\/aiua.2017.3.197","article-title":"Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial","volume":"89","author":"Micali","year":"2017","journal-title":"Arch Ital Urol Androl"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0171","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/pros.22943","article-title":"Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy","volume":"75","author":"Henning","year":"2015","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0172","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1940-6207.CAPR-08-0167","volume":"2","author":"McLarty","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0173","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1940-6207.CAPR-11-0306","article-title":"Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: Evaluation of potential chemopreventive activities","volume":"5","author":"Nguyen","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0174","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urolonc.2004.10.008","article-title":"A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary\/alternative therapy approach","volume":"23","author":"Choan","year":"2005","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0175","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.11200","article-title":"A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma","volume":"97","author":"Jatoi","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.semradonc.2026.151031_bib0176","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/lt.21021","article-title":"Acute liver failure induced by green tea extracts: case report and review of the literature","volume":"12","author":"Molinari","year":"2006","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0177","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-144-1-200601030-00020","article-title":"Hepatotoxicity associated with supplements containing Chinese green tea (camellia sinensis)","volume":"144","author":"Bonkovsky","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semradonc.2026.151031_bib0178","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.yrtph.2018.03.019","article-title":"The safety of green tea and green tea extract consumption in adults \u2013 results of a systematic review","volume":"95","author":"Hu","year":"2018","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0179","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/pcan.2014.6","article-title":"A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer\u2013the U.K. NCRN Pomi-T study","volume":"17","author":"Thomas","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/pcan.2017.19","article-title":"A review of pomegranate in prostate cancer","volume":"20","author":"Paller","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.semradonc.2026.151031_bib0181","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-psych-042716-051139","article-title":"Mindfulness interventions","volume":"68","author":"Creswell","year":"2017","journal-title":"Annu Rev Psychol"},{"issue":"10","key":"10.1016\/j.semradonc.2026.151031_bib0182","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/pon.5749","article-title":"Mindfulness-based interventions for psychological wellbeing and quality of life in men with prostate cancer: A systematic review and meta-analysis","volume":"30","author":"Nnate","year":"2021","journal-title":"Psychooncology"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0183","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2016.68.8788","article-title":"Mindfulness-based cognitive therapy in advanced prostate cancer: A randomized controlled trial","volume":"35","author":"Chambers","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2026.151031_bib0184","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/pon.4135","article-title":"Feasibility, acceptability and preliminary psychological benefits of mindfulness meditation training in a sample of men diagnosed with prostate cancer on active surveillance: Results from a randomized controlled pilot trial","volume":"26","author":"Victorson","year":"2017","journal-title":"Psychooncology"},{"key":"10.1016\/j.semradonc.2026.151031_bib0185","article-title":"Implementation readiness and initial effects of a brief mindfulness audio intervention compared with a brief music control during daily radiation therapy for prostate cancer: A randomized pilot study","volume":"13","author":"Victorson","year":"2024","journal-title":"Glob Adv Integr Med Health"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0186","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11764-017-0665-5","article-title":"Tai Chi and Qigong for cancer-related symptoms and quality of life: A systematic review and meta-analysis","volume":"12","author":"Wayne","year":"2018","journal-title":"J Cancer Surviv"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0187","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/pon.4256","article-title":"Qigong\/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: A randomized controlled trial","volume":"26","author":"McQuade","year":"2017","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0188","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11764-013-0315-5","article-title":"Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong","volume":"8","author":"Campo","year":"2014","journal-title":"J Cancer Surviv"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0189","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s13063-021-05687-7","article-title":"Protocol for GET FIT Prostate: A randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer","volume":"22","author":"Winters-Stone","year":"2021","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.semradonc.2026.151031_bib0190","first-page":"553","article-title":"Effect of yoga as a complementary therapy in prostate cancer survivors: A systematic review","volume":"32","author":"Boopalan","year":"2024","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0191","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ijrobp.2017.03.043","article-title":"Effect of Eischens yoga during radiation therapy on prostate cancer patient symptoms and quality of life: A randomized phase II trial","volume":"98","author":"Ben-Josef","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2026.151031_bib0192","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-021-00470-w","article-title":"Effects of yoga in men with prostate cancer on quality of life and immune response: A pilot randomized controlled trial","volume":"25","author":"Kaushik","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"52","key":"10.1016\/j.semradonc.2026.151031_bib0193","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgx005","article-title":"The National Cancer Institute's Conference on Acupuncture for Symptom Management in Oncology: State of the science, evidence, and research gaps","volume":"2017","author":"Zia","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0194","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaoncol.2025.1199","article-title":"Acupuncture for nocturia in survivors of prostate cancer: the NOCTURNAL randomized clinical trial","volume":"11","author":"Liou","year":"2025","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.34491","article-title":"Electroacupuncture in patients with early urinary incontinence after radical prostatectomy: A randomized clinical trial","volume":"8","author":"Niu","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semradonc.2026.151031_bib0196","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2023.102490","article-title":"Effectiveness of auricular acupuncture and pelvic floor muscle training in the management of urinary incontinence following surgical treatment for prostate cancer: A randomized clinical trial","volume":"68","author":"Azevedo","year":"2024","journal-title":"Eur J Oncol Nurs"},{"issue":"6","key":"10.1016\/j.semradonc.2026.151031_bib0197","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bju.16288","article-title":"A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy","volume":"133","author":"Maurer","year":"2024","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0198","first-page":"763","article-title":"Acupuncture for treating hot flushes in men with prostate cancer: A systematic review","volume":"17","author":"Lee","year":"2009","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0199","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.urology.2010.03.033","article-title":"Acupuncture for hot flashes in patients with prostate cancer","volume":"76","author":"Beer","year":"2010","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0200","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ijrobp.2010.01.025","article-title":"Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy","volume":"79","author":"Ashamalla","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0201","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12906-023-04218-y","article-title":"Acupuncture versus sham acupuncture and usual care for antiandrogen-induced hot fLashes in prostate cancer (AVAIL): Study protocol for a randomized clinical trial","volume":"23","author":"Qin","year":"2023","journal-title":"BMC Complement Med Ther"},{"issue":"11","key":"10.1016\/j.semradonc.2026.151031_bib0202","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/cncr.34165","article-title":"Safety of acupuncture in oncology: A systematic review and meta-analysis of randomized controlled trials","volume":"128","author":"H\u00f6xtermann","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2026.151031_bib0203","series-title":"The Oxford Handbook of Music Therapy","first-page":"112","article-title":"Music therapy with adults diagnosed with cancer and their families","author":"O\u2019Callaghan","year":"2016"},{"key":"10.1016\/j.semradonc.2026.151031_bib0204","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2022.102913","article-title":"The effect of music therapy on anxiety and pain in patients undergoing prostate biopsy: A systematic review and meta-analysis","volume":"72","author":"He","year":"2023","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.semradonc.2026.151031_bib0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1292577","article-title":"Incidence trends in prostate cancer among men in the United States from 2000 to 2020 by race and ethnicity, age and tumor stage","volume":"13","author":"Du","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0206","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2016.10.036","article-title":"Racial variation in patient-reported outcomes following treatment for localized prostate cancer: Results from the CEASAR study","volume":"72","author":"Tyson","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0207","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41391-022-00608-4","article-title":"The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer","volume":"26","author":"Posielski","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.semradonc.2026.151031_bib0208","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/OP.24.00076","article-title":"Demographic and clinical factors associated with health-related quality-of-life profiles among prostate cancer survivors","volume":"20","author":"Potosky","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0209","first-page":"144","article-title":"Integrative oncology: Addressing the global challenges of cancer prevention and treatment","volume":"72","author":"Mao","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.semradonc.2026.151031_bib0210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10900-021-01046-4","article-title":"Use of complementary and alternative medicine for prostate cancer among African Americans, African Immigrants and Caribbean immigrants","volume":"47","author":"Malika","year":"2022","journal-title":"J Community Health"},{"key":"10.1016\/j.semradonc.2026.151031_bib0211","doi-asserted-by":"crossref","DOI":"10.1200\/OP-25-00321","article-title":"Program evaluation of acupuncture and massage services delivered for symptom management at a community cancer clinic","author":"Booher","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.semradonc.2026.151031_bib0212","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jpainsymman.2022.07.007","article-title":"Music therapy for pain in black and white cancer patients: a retrospective study","volume":"64","author":"Lichtl","year":"2022","journal-title":"J Pain Symptom Manage"},{"issue":"16","key":"10.1016\/j.semradonc.2026.151031_bib0213","doi-asserted-by":"crossref","first-page":"e7344","DOI":"10.1002\/cam4.7344","article-title":"Racial differences in treatment adherence and response to acupuncture and cognitive behavioral therapy for insomnia among Black and White cancer survivors","volume":"13","author":"Liou","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.semradonc.2026.151031_bib0214","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2025.107973","article-title":"Exercise to enhance cardiovascular health among black men with prostate cancer with androgen deprivation therapy (the POWER trial): a study protocol","volume":"155","author":"Kang","year":"2025","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.semradonc.2026.151031_bib0215","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae119","article-title":"Cancer clinical trial participation: a qualitative study of black\/African American communities' and patient\/survivors' recommendations","volume":"9","author":"Kaljee","year":"2025","journal-title":"JNCI Cancer Spectr"},{"issue":"9","key":"10.1016\/j.semradonc.2026.151031_bib0216","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/OP.21.00863","article-title":"A scoping review of strategies to increase black enrollment and retention in cancer clinical trials","volume":"18","author":"Arring","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.semradonc.2026.151031_bib0217","first-page":"225","article-title":"American Cancer Society prostate cancer survivorship care guidelines","volume":"64","author":"Skolarus","year":"2014","journal-title":"CA Cancer J Clin"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429626000330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429626000330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:49:01Z","timestamp":1783028941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429626000330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":217,"alternative-id":["S1053429626000330"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2026.151031","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative Oncology for Prostate Cancer: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2026.151031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151031"}}